This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment. Obesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success. In this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed: * Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels * Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels * Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS) * Anthropometric measurements: body weight, height, waist and hip circumference, BMI * Nutritional intake: 3-day dietary records The study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.
Age range
19 Years – 50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change in Fasting Blood Glucose Concentration (mg/dL)
Timeframe: Baseline and 6 months
Change in Total Cholesterol Concentration (mg/dL)
Timeframe: Baseline and 6 months
Change in Triglyceride Concentration (mg/dL)
Timeframe: Baseline and 6 months
Change in HDL Cholesterol Concentration (mg/dL)
Timeframe: Baseline and 6 months
Change in LDL Cholesterol Concentration (mg/dL)
Timeframe: Baseline and 6 months
Change in VLDL Cholesterol Concentration (mg/dL)
Timeframe: Baseline and 6 months
Change in Fasting Insulin Concentration (µIU/mL)
Timeframe: Baseline and 6 months
Change in Serum Zonulin Concentration (ng/mL)
Timeframe: Baseline and 6 months
Change in Serum Secretory IgA Concentration (mg/dL)
Timeframe: Baseline and 6 months
Change in Serum LPS Concentration (EU/mL)
Timeframe: Baseline and 6 months
Change in Gastrointestinal Symptom Rating Scale (GSRS) Total Score (1-7)
Timeframe: Baseline and 6 months